{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=33", "query": { "intervention": "Control II", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 2665, "total_pages": 267, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T06:05:03.778Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02349009", "title": "Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Scleroderma" ], "interventions": [ { "name": "C-82 Topical Gel, 1%", "type": "DRUG" }, { "name": "C-82 Topical Gel, Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prism Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-06", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349009" }, { "nct_id": "NCT02144571", "title": "Sistas Inspiring Sistas Through Activity and Support", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prevention Harmful Effects" ], "interventions": [ { "name": "Lifestyle", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "30 Years to 90 Years · Female only" }, "enrollment_count": 350, "start_date": "2010-11", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 1, "location_summary": "Columbia, South Carolina", "locations": [ { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144571" }, { "nct_id": "NCT03800134", "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 825, "start_date": "2018-12-06", "completion_date": "2028-09-11", "has_results": false, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Duarte, California • Orange, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800134" }, { "nct_id": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Dovitinib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 97, "start_date": "2012-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 18, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528345" }, { "nct_id": "NCT00158600", "title": "A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pompe Disease (Late-onset)", "Glycogen Storage Disease Type II (GSD-II)", "Acid Maltase Deficiency Disease", "Glycogenosis 2" ], "interventions": [ { "name": "alglucosidase alfa", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 90, "start_date": "2005-09", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 5, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00158600" }, { "nct_id": "NCT02600507", "title": "Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Depression" ], "interventions": [ { "name": "Lumateperone (ITI-007)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intra-Cellular Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 529, "start_date": "2016-03-07", "completion_date": "2020-07-02", "has_results": true, "last_update_posted_date": "2023-05-17", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 42, "location_summary": "Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600507" }, { "nct_id": "NCT03934099", "title": "A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout", "Hyperuricemia" ], "interventions": [ { "name": "LC350189 formulated capsule", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LG Chem", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 156, "start_date": "2019-12-02", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934099" }, { "nct_id": "NCT04323436", "title": "Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Capmatinib", "type": "DRUG" }, { "name": "spartalizumab placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-08-19", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323436" }, { "nct_id": "NCT06947993", "title": "Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "GHZ339", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 224, "start_date": "2025-05-16", "completion_date": "2028-12-22", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06947993" }, { "nct_id": "NCT00086606", "title": "A Safety and Efficacy Study of Xolair in Peanut Allergy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergy" ], "interventions": [ { "name": "Xolair (omalizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Years to 75 Years" }, "enrollment_count": 150, "start_date": "2004-06", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-01-21", "last_synced_at": "2026-10-25T06:05:03.778Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086606" } ] }